Apollo’s Covis sues over preterm-birth drug patents
Aurobindo’s subsidiary Eugia allegedly infringed two patents for an injectable treatment for reducing the risk of premature birth, according to a lawsuit by Covis Pharma, a Luxembourg-based unit of Apollo Global Management.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
8 January 2020 Allergan’s Warner Chilcott and Watson subsidiaries have agreed to pay $300 million to end antitrust litigation centering on contraceptive pills Loestrin 24 Fe and Minastrin 24 Fe.
24 October 2014 A US court has rejected attempts by two companies to market generic versions of a birth control pill owned by pharmaceutical company Actavis.